Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 1

A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease

NCT07106021 · View on ClinicalTrials.gov ↗

Study Summary

This clinical trial is designed to test the safety and tolerability of the study intervention, RNDP-001, which will be implanted into the brain of study participants during a surgical procedure.

Interventions

  • BIOLOGICAL RNDP-001
  • DEVICE Syringe Front-Loading Device

Study Locations (3)

Arizona

  • University of Arizona — Tucson

California

  • Keck Medical Center of University of Southern California — Los Angeles

Ohio

  • The Ohio State University Wexner Medical Center — Columbus

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2025-07-17
Est. Completion 2031-06
Phase Phase 1

Sponsor

Kenai Therapeutics

32 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07106021

The ClinicalTrials.gov registry entry for NCT07106021 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kenai Therapeutics, which has 32 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions — of which RNDP-001 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07106021 reports 3 study locations spanning 3 distinct geographic areas — top geographies include Arizona, California, Ohio. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07106021 about?

NCT07106021 is a clinical study titled "A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease". This clinical trial is designed to test the safety and tolerability of the study intervention, RNDP-001, which will be implanted into the brain of study participants during a surgical procedure.

What is the current status of trial NCT07106021?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-07-17. Estimated completion is 2031-06.

What conditions does trial NCT07106021 study?

This clinical trial studies the following conditions: Parkinson's Disease, Idiopathic Parkinson´s Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07106021?

The interventions under investigation include: RNDP-001 (BIOLOGICAL), Syringe Front-Loading Device (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07106021?

This trial is sponsored by Kenai Therapeutics, which has 32 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07106021 being conducted?

This trial has 3 study locations across Arizona, California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial